Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Delanoy

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trialsDebbie G Robbrecht, Nicolas Delanoy, Ian F Tannock, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 18, 2020
Nephrotoxicity Associated With NiraparibHélène Lazareth, Nicolas Delanoy, Raphaël Cohen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 10, 2021
Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancerLouise Benoit, Meriem Koual, Marie-Aude Le Frère-Belda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 14, 2025
Factors associated with medication adherence trajectory among patients treated with oral anticancer drugs: a multicentre cohort studyGermain Perrin, Audrey Thomas-Schoemann, François Goldwasser, et al.
Gynecologic Oncology|July 4, 2021
What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?Louise Benoit, Jonathan Zerbib, Meriem Koual, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 30, 2025
Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective studyElisabeth Ashton, Nicolas Delanoy, Rym El Gharib, et al.
Bulletin Du Cancer|November 21, 2021
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers]Marjolaine Le Gac, Meriem Koual, Nicolas Delanoy, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Bulletin Du Cancer|September 2, 2023
Real-world dostarlimab use in advanced/recurrent endometrial cancer in FranceManuel Rodrigues, Lauriane Eberst, Philippe Follana, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trialsDebbie G Robbrecht, Nicolas Delanoy, Ian F Tannock, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 18, 2020
Nephrotoxicity Associated With NiraparibHélène Lazareth, Nicolas Delanoy, Raphaël Cohen, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 10, 2021
Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancerLouise Benoit, Meriem Koual, Marie-Aude Le Frère-Belda, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 14, 2025
Factors associated with medication adherence trajectory among patients treated with oral anticancer drugs: a multicentre cohort studyGermain Perrin, Audrey Thomas-Schoemann, François Goldwasser, et al.
Gynecologic Oncology|July 4, 2021
What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?Louise Benoit, Jonathan Zerbib, Meriem Koual, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 30, 2025
Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective studyElisabeth Ashton, Nicolas Delanoy, Rym El Gharib, et al.
Bulletin Du Cancer|November 21, 2021
[Place of PARP inhibitors in the treatment of endometrial and cervical cancers]Marjolaine Le Gac, Meriem Koual, Nicolas Delanoy, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Bulletin Du Cancer|September 2, 2023
Real-world dostarlimab use in advanced/recurrent endometrial cancer in FranceManuel Rodrigues, Lauriane Eberst, Philippe Follana, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Pageof 4